Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700377 | 0.87 | PDK2 (0.34) | DYRK1AFFAR4PTGER3 | |
| SCHEMBL3700385 | 0.86 | DYRK1A (0.30) | DYRK1AFFAR4 | |
| SCHEMBL4131192 | 0.83 | CTSD (0.34) | DYRK1AAR | |
| SCHEMBL4119122 | 0.83 | AR (0.33) | DYRK1AFFAR4AR | |
| SCHEMBL3799051 | 0.83 | ALDH1A1 (0.35) | DYRK1AAR | |
| SCHEMBL4130796 | 0.82 | MGAM (0.36) | DYRK1AAR | |
| SCHEMBL4132224 | 0.82 | DYRK1A (0.34) | DYRK1AFFAR4PTGER3 | |
| SCHEMBL4130271 | 0.82 | GLA (0.34) | — | |
| SCHEMBL4125110 | 0.82 | AR (0.32) | DYRK1AAR | |
| SCHEMBL4119012 | 0.80 | LIPG (0.32) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | DYRK1A 4742/4885FFAR4 224/4885AR 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.